Immunisation schedule of the Spanish Association of Paediatrics : 2023 Recommendations
Copyright © 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved..
As it does every year, the CAV-AEP publishes the update of its recommendations for the use of vaccines in children, adolescents and pregnant women residing in Spain. The 2 + 1 schedule is maintained in infants (at 2, 4 and 11 months), including preterm infants, with the hexavalent vaccine (DTaP-IPV-Hib-HB) and the pneumococcal 13-valent conjugate vaccine. A booster dose with DTaP-IPV is needed at 6 years for those who received the 2 + 1 series with hexavalent vaccine as infants, in addition to 1 dose of dTap in adolescence. Routine vaccination of pregnant women with a dose of dTap is recommended in each pregnancy, preferably between weeks 27 and 32 of gestation, although can be given from 20 weeks if there is risk of preterm delivery. All infants should receive the rotavirus vaccine (2-3 doses) and the 4CMenB vaccine (2 + 1 series). All children aged 6-59 months should be vaccinated against influenza each year. The MenACWY vaccine should be given routinely at 12 months of age and in adolescence between ages 12 and 18 years. The recommendations for the MMR vaccine (12 months and 3-4 years) and varicella vaccine (15 months and 3-4 years) also remain unchanged, using the MMRV vaccine for the second dose. Recommendations for the use of SARS-CoV-2 vaccines in the paediatric age group will be updated periodically on the CAV-AEP website. The HPV vaccine is indicated in all adolescents, regardless of sex, at age 12 years. Novelties include the recommendation of routine administration of nirsevimab to neonates and infants aged less than 6 months for passive immunization against RSV, and the recommendations regarding the hexavalent vaccine are consolidated in a single section.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:98 |
|---|---|
| Enthalten in: |
Anales de pediatria - 98(2023), 1 vom: 20. Jan., Seite 58.e1-58.e10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Álvarez García, Francisco José [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.01.2023 Date Revised 11.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anpede.2022.11.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351107096 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351107096 | ||
| 003 | DE-627 | ||
| 005 | 20231226050539.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anpede.2022.11.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351107096 | ||
| 035 | |a (NLM)36599520 | ||
| 035 | |a (PII)S2341-2879(22)00233-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Álvarez García, Francisco José |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunisation schedule of the Spanish Association of Paediatrics |b 2023 Recommendations |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2023 | ||
| 500 | |a Date Revised 11.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a As it does every year, the CAV-AEP publishes the update of its recommendations for the use of vaccines in children, adolescents and pregnant women residing in Spain. The 2 + 1 schedule is maintained in infants (at 2, 4 and 11 months), including preterm infants, with the hexavalent vaccine (DTaP-IPV-Hib-HB) and the pneumococcal 13-valent conjugate vaccine. A booster dose with DTaP-IPV is needed at 6 years for those who received the 2 + 1 series with hexavalent vaccine as infants, in addition to 1 dose of dTap in adolescence. Routine vaccination of pregnant women with a dose of dTap is recommended in each pregnancy, preferably between weeks 27 and 32 of gestation, although can be given from 20 weeks if there is risk of preterm delivery. All infants should receive the rotavirus vaccine (2-3 doses) and the 4CMenB vaccine (2 + 1 series). All children aged 6-59 months should be vaccinated against influenza each year. The MenACWY vaccine should be given routinely at 12 months of age and in adolescence between ages 12 and 18 years. The recommendations for the MMR vaccine (12 months and 3-4 years) and varicella vaccine (15 months and 3-4 years) also remain unchanged, using the MMRV vaccine for the second dose. Recommendations for the use of SARS-CoV-2 vaccines in the paediatric age group will be updated periodically on the CAV-AEP website. The HPV vaccine is indicated in all adolescents, regardless of sex, at age 12 years. Novelties include the recommendation of routine administration of nirsevimab to neonates and infants aged less than 6 months for passive immunization against RSV, and the recommendations regarding the hexavalent vaccine are consolidated in a single section | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adolescent | |
| 650 | 4 | |a Adolescente | |
| 650 | 4 | |a Calendario de inmunización español | |
| 650 | 4 | |a Child | |
| 650 | 4 | |a Childhood vaccines | |
| 650 | 4 | |a Embarazada | |
| 650 | 4 | |a Infant | |
| 650 | 4 | |a Lactante | |
| 650 | 4 | |a Niño | |
| 650 | 4 | |a Pregnant | |
| 650 | 4 | |a Spanish immunisation schedule | |
| 650 | 4 | |a Vacunas infantiles | |
| 650 | 7 | |a Meningococcal Vaccines |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Bacterial Vaccines |2 NLM | |
| 650 | 7 | |a Rotavirus Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Combined |2 NLM | |
| 700 | 1 | |a Cilleruelo Ortega, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Álvarez Aldeán, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Garcés-Sánchez, María |e verfasserin |4 aut | |
| 700 | 1 | |a Garrote Llanos, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Iofrío de Arce, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Montesdeoca Melián, Abián |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro Gómez, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pineda Solas, Valentín |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero Calle, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Contreras, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano Marchuet, Pepe |e verfasserin |4 aut | |
| 700 | 0 | |a en representación del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anales de pediatria |d 2010 |g 98(2023), 1 vom: 20. Jan., Seite 58.e1-58.e10 |w (DE-627)NLM19488628X |x 2341-2879 |7 nnns |
| 773 | 1 | 8 | |g volume:98 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:58.e1-58.e10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anpede.2022.11.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 98 |j 2023 |e 1 |b 20 |c 01 |h 58.e1-58.e10 | ||